Immunogen Inc. | Ownership
Companies that own Immunogen Inc.
Redmile Group LLC
12,315,942
8.27%
2,613,460
3.89%
06/30/2018
BlackRock Fund Advisors
9,653,748
6.48%
1,847,034
0.01%
06/30/2018
The Vanguard Group, Inc.
9,504,949
6.38%
808,893
0%
06/30/2018
Capital Research & Management Co. (Global Investors)
9,431,000
6.33%
3,923,000
0.02%
06/30/2018
ClearBridge Investments LLC
9,165,030
6.15%
-414,419
0.08%
06/30/2018
SSgA Funds Management, Inc.
8,996,007
6.04%
1,758,759
0.01%
06/30/2018
Fidelity Management & Research Co.
8,682,134
5.83%
2,186,696
0.01%
06/30/2018
Renaissance Technologies LLC
6,525,300
4.38%
1,719,360
0.07%
06/30/2018
PRIMECAP Management Co.
3,823,300
2.57%
0
0.03%
06/30/2018
OrbiMed Advisors LLC
2,904,270
1.95%
1,400,000
0.31%
06/30/2018
| Address |
830 Winter Street
Waltham Massachusetts 02451
United States
|
|
Employees
|
- |
| Website |
http://www.immunogen.com |
| Updated |
07/08/2019 |
| ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779, and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA. |
